The biomarkers of immune dysregulation and inflammation response in Parkinson disease by Chen, Li et al.
The biomarkers of immune
dysregulation and inflammation
response in Parkinson disease
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Chen, L., M. Mo, G. Li, L. Cen, L. Wei, Y. Xiao, X. Chen, et al. 2016.
“The biomarkers of immune dysregulation and inflammation
response in Parkinson disease.” Translational Neurodegeneration
5 (1): 16. doi:10.1186/s40035-016-0063-3. http://dx.doi.org/10.1186/
s40035-016-0063-3.
Published Version doi:10.1186/s40035-016-0063-3
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:29002417
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
REVIEW Open Access
The biomarkers of immune dysregulation
and inflammation response in Parkinson
disease
Li Chen1, Mingshu Mo1, Guangning Li7, Luan Cen2, Lei Wei1,3, Yousheng Xiao2, Xiang Chen1, Shaomin Li4*,
Xinling Yang5*, Shaogang Qu6* and Pingyi Xu1,2*
Abstract
Parkinson’s disease (PD) is referring to the multi-systemic α-synucleinopathy with Lewy bodies deposited in
midbrain. In ageing, the environmental and genetic factors work together and overactive major histocompatibility
complex pathway to regulate immune reactions in central nerve system which resulting in neural degeneration,
especially in dopaminergic neurons. As a series of biomarkers, the human leukocyte antigen genes with its related
proteomics play cortical roles on the antigen presentation of major histocompatibility complex molecules to
stimulate the differentiation of T lymphocytes and i-proteasome activities under their immune response to the
PD-related environmental alteration and genetic variation. Furthermore, dopaminergic drugs change the biological
characteristic of T lymphatic cells, affect the α-synuclein presentation pathway, and inhibit T lymphatic cells to
release cytotoxicity in PD development. Taking together, the serum inflammatory factors and blood T cells are
involved in the immune dysregulation of PD and inspected as the potential clinic biomarkers for PD prediction.
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Background
The raised incidence of Parkinson’s disease (PD) becomes
a serious issue in an aged society [1]. It is known that PD
patients in Asia is nearby 11.3 % of movement disorders,
slightly lower than that in north America which is up to
13.6 % and 16.6 % of Europe [1]. Based on the characteris-
tic protein conformation and function, central nervous de-
generative diseases involved in movement disorders can
be clinically classed as α-synucleinopathy, Tauopathy and
TDP-43 proteinopathy in which PD belongs to α-synuclei-
nopathy [2]. According to the latest clinic diagnosis cri-
teria of MDS (Movement Disorder Association 2015), the
diagnosis of PD need to meet the following criteria: rest
tremor and bradykinesia in limbs, clinic symptoms of PD
are effectively improved by L-dopa, disease duration is
usually accompanied by non-motor symptoms especially
in early stage, and discrimination from other neural dis-
ease [3]. The various types of α-synuclein manifest mainly
as monomers, oligomers, ribbons and fibrils, and a-
synuclein diffuses through blood brain barrier, spread
around whole nervous system, even invade other tissues
or organs such as nasal mucosa, skin, kidney, liver, heart,
intestinal tract and salivary glands [4, 5]. As well-known,
aging is confirmed to be an important risk to PD [6].
Other risk factors include harmful environment factors
and deficient genetic factors [6]. It's worth noting that en-
vironment factors such as MPTP, LPS, rotenone or other
organic chemicals not only impair dopaminergic (DA)
neurons directly and render the epigenetic variation of
DNA methylation, but also activate the secondary inflam-
mation/immunity reaction and significantly increase the
PD morbidity [7, 8].
Immunologic dysregulation in PD
Recently immunologic systems were found in central
neural system (CNS) which involved with PD [9]. The
classic concepts pointed out that central immune system
is not directly connected with extracranial system. How-
ever, latest reports demonstrated that lymphatic ducts
hind in the meninge and link to deep cervicalvenous sys-
tem in which abundant T, B lymphocytes and dendritic
cells are response to environment and genetic variation
[10]. According to recent dynamic experiments, the
lymphatic system plays an important role in the drainage
of spinal fluid to lymphatic duct oriented into deep cer-
vical venous system [10]. This discovery revealed that
there is a close linkage between the meninge lymphatic
system and α-synuclein transmission. The brain autopsy
from PD patients and PD animal models showed that
abnormal accumulation of microglia were activated in
brain tissues, especially in nigrostriatal area [11]. Under
the abnormal inflammation condition, macrophages
pathologically diffuse from blood vessels to CNS and
transform into microglias contributed to the pathological
development of intracranial neural diseases [12]. Mean-
while the activated T lymphocytes were demonstrated to
move out from central lymph ducts to attack central
neurons, neural myelination or fibers, which resulting in
multiple neuropathy as multiple sclerosis like symptoms
[13]. In 6-hydroxydopamine-PD rats, there were abun-
dant CD3+, CD4+, CD8+ T lymph cells migrated from
blood vessels into substantia nigra (SN) to attack DA
neurons [13, 14]. Therefore, it is reasonable to suppose
these lymph cells could be the potential biomarkers for
the evaluation of PD progression [14].
Immunoproteasome system in PD
The α-synuclein aggregation is a critical ignition role for
the immune disorder in PD [15]. In aging process, the
progressive dysfunction of T, B lymph cells and macro-
phages were related with immune elimination which
gradually gave rise to α-synuclein aggregation and
neurons degeneration [16, 17]. Furthermore, due to the
decreased activity of proteasome, its components as
β1,β2 and β5 subunits which compose of 20S prote-
asome will be replaced by homogenous β1i (large multi-
functional protease 2, LMP2), β2i (multi catalytic endo-
peptidase complex-like-1, MECL-1) and β5i (large multi-
functional protease 7, LMP7) subunits and develop a
new immunoproteasome system named as i-proteasome
[18]. The crystal structure showed that i-proteasomes
have more enzyme domains, stronger enzymatic activity,
and more effective capacity to degrade the α-synuclein
proteins. Particularly, i-proteasome presents the de-
graded peptides as antigens to special T cells [19]. These
antigens combined with major histocompatibility com-
plex molecules (MHC) to ignite another pattern of pro-
tein clearance or abnormal neural inflammation [19]. It
was reported that i-proteasome was up-regulated in se-
nile hippocampus which involves in the clearance of ac-
cumulated amyloid precursor protein (APP) in
Alzheimer's disease (AD) [20]. In epilepsy, the i-
proteasomes activated by oxidative damaged proteins
can maintain the stability of protein metabolism in brain
[21]. There are seven i-proteasome cleavage sites in the
amino acid sequence of α-synuclein (sequence No.100,
8, 10, 55, 125, 45 and 18, respectively) [22]. Among
them, No. 10 and 45 amino acid locate at N terminal
named as KTKEGV sequence [22]. This KTKEGV se-
quence is vital to keep the metabolic stability of α-
synuclein [22]. The i-proteasomes mainly guide the
MHC molecules to mediate inflammation/immunity re-
action, however we did not completely understand the
detail about i-proteasomes participating in PD pathogen-
esis. It is known that after the α-synuclein degraded into
5–15 amino acid residues by ubiquitin proteasome sys-
tem (UPS), the short antigenic peptides will be trans-
ported into endoplasmic reticulum system by the
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transporter associated with antigen processing (TAP)
which brought the antigenic peptides to cell surfaces
and the complex will be recognized by the MHC-I and
MHC-II receptors. Then MHC presentation activates
CD4+T cells and CD8+cytotoxic T lymphocytes (CTL) to
take part in the immune regulation in CNS, respectively
[23]. Human MHC molecules are also called human
leukocyte antigen (HLA). DA neurons express multiple
HLA molecules and present the digested peptides on the
surface recognized by CD8+ CTL cells [23]. At the same
time, the activated microglias secrete TNF-α, IL-1β and
IL-6 inflammatory factors to attack DA neurons, or
present antigens to CD4+ T cells by MHC-II pathway
[24, 25]. Abundant MHC-II positive microglia and CD4
+,CD8+ T cells were found in the SN of PD patients, and
the microglia activity was confirmed to be related to the
degeneration severity of DA neurons as well as PD pro-
gression [17]. Our data found that natural killer (NK)
cells increased and CD3+T, CD3+CD4+T cells, Th1 cells
decreased in the peripheral blood from PD patients [26].
These immune reactions will result in the increased se-
cretion of TNF-α, IL-2, IL-6, IL-10, IL-1β and IFN-γ in
cerebrospinal fluid (CSF) or blood, and accompanied
with more than ten kinds of high sensitive and specific
antibodies increased, such as elongation factor 1-alpha1
and poly (A) binding protein cytoplasmic-3 [25, 27]. The
surface antigens in monocytes were up-regulated and
correlated with the Unified Parkinson's Disease Rating
Scale (UPDRS) III scores of PD patients, indicating the
importance of central and peripheral immunity reaction
occurred in PD [28]. Recent studies showed that HLA-I
in DA neurons and HLA-II in activated microglia both
participate the antigen presentation and α-synuclein
degradation [24, 29]. When proteasome function is sup-
pressed by intracellular α-synuclein accumulation, i-
proteasome will be activated as compensatory to promote
α-synuclein degradation [30]. The degraded peptides will
be presented to CD8+T cells by MHC-I molecules, and the
CD8+T cells release pre-inflammatory factors and activate
Wnt/Nurr1 and Nuclear factor-kB signal pathways to ig-
nite the secondary inflammation reaction [30, 31]. Mean-
while, extracellular α-synuclein integrates with HLA-DR
molecules in microglia, mediate the activation of CD4+T
cells by MCH-II antigen presentation pathway and T lym-
phocytes to participate the immune reaction in CNS [15,
25]. If the proteasomes function are impaired in DA neu-
rons, α-synuclein accumulation could activate the i-
proteasomeas as compensatory to provide much more
MHC-I and MHC-II molecules to CD8+T and CD4+ T
cells showing stronger immune response [29, 32]. Under
the condition of HLA gene mutation, the genetic risks
may profoundly affect the α-synuclein degradation, result
in the immune dysregulation in CNS and finally accelerate
the DA neurons apoptosis.
Immunological genes involved in PD
It is well known that genetic factors has high risk for
PD. Much data revealed that the variation of HLA
genes severely accelerate PD development [33]. Total
224 genes in HLA region are located at I, II and III
region of HLA genomics, respectively [33]. Excepted
the rarely expressed genes at HLA-I region, 128 genes
from II and III of HLA region were found the contri-
bution to immune regulation in CNS [33]. For ex-
ample, HLA-DR at HLA II region is composed of
DRA and DRB genes which encoding α and β chain
respectively [33]. The α and β chains are assembled
into HLA-DR molecules contributed to the immuno-
logic response in neuron degeneration [33]. It's worth
noting that HLA genes have high polymorphism
among different ethnic and geographical population
[34]. For example, HLA-C*0304, HLA-DRB1*0404,
HLA-DRA and HLA-DQB1 were closely related to
PD in European population, but no reports in
Japanese [33, 34]. Our investigation firstly showed
that HLA-DRB1*0301 is a suspect locus to PD in Chinese
Han population (OR = 2.048,95%CI:1.455,2.884), but no
meaningful polymorphism found in Chinese Uyghur
population [34]. It is known that proteasome subunit beta
(PSMB) genes locate at HLA-II region and adjacent to
HLA-DR genes [33]. PSMB genes encodes β chain to help
the α-synuclein degradation after the proteasome consti-
tution [35]. It was speculated that PSMB may cooperate
with HLA-DR to participate the immune regulation and
intrinsic antigen presentation [36]. Our investigation has
confirmed that female carrying rs17587 G/G at PSMB9
will significantly increase PD risk (OR = 1.851 95%CI:
1.240). The rs17587 locates at the code region of exon 60
at PSMB9 [33]. Its variation of nucleotide G to A may lead
to the amino acid of arginine replaced with histidine [37].
The G/G genotype of rs17587 at PSMB9 disrupts the pep-
tide cleavage site of proteasome resulting in the impaired
activity of proteasome [37]. Other important genes are re-
ported to involve in immunological regulation of PD, in-
cluded HLA, GBA (Glucosidase Beta Acid), SNCA
(Synuclein alpha), LRRK2 (Leucine-rich repeat kinase 2)
and NURR1 (Nuclear receptor related 1 protein) [33, 38].
The GBA protein is liable to regulate the abnormal activa-
tion of microglia in basal ganglia [39], and the LRRK2 pro-
tein may affect the inflammatory reaction medicated by
Toll-like receptor 4 [40]. Nurr1, a new anti-inflammatory
factor, regulate the nuclear factor-kB-p65 signaling path-
way in microglia and astrocytes through Nurr1/CoREST
(RE1-silencing transcription factor co-repressor 1) com-
plex [41]. Generally, variations in these PD-related genes
may promote the antigen presentation and the activation
of T and B lymphocytes, strengthen the sensitivity of DA
neurons to environmental risk, and down-regulate the cat-
echolamine metabolism conducted by MHC pathway [34].
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In other words, it was suggested these genetic factors,
serum immune/inflammatory molecules and blood lym-
phocytes may be the potential clinic biomarkers for PD
prediction.
Dopamine receptors in blood lymphocytes
Dopamine receptors were found in the blood white cells
of human kind [42]. These receptors are moderately
expressed in neutrophil granulocyte or eosinophil gran-
ulocyte, but highly expressed in B lymphocytes and NK
cells [42]. There are five kinds of dopamine receptors in
CD3+CD4+T lymphocytes with different expression level
[42]. For example, the D1 receptor expression is signifi-
cantly higher than D2, and D5 receptor expression is
higher than D1 in T lymphocytes and memory T
lymphocytes [42]. The D2 receptor showed no signifi-
cant different expression in blood cells from PD patient
[42, 43]. But the D3 receptor expression declines dra-
matically in peripheral lymphocytes and is associated
with PD severity [42]. The proportion of CD95/CD3 in-
creases significantly in the lymphocytes from PD
patients, but decreases significantly after L-dopa treat-
ment [44]. The activation of dopamine receptors by dif-
ferent activators can reduce the release of TNF-α, IL-6
and other cytokines from microglia which may help to
explain their neuro-protection [45, 46].
MicroRNA signatures in PD
Recent studies demonstrated that some PD-related genes
is modulated by 18 ~ 25 nt microRNAs (miRNAs) [47]
at post-transcriptional level. Matching with target
mRNA 3′ transcription terminals, miRNAs guide Dicer
enzyme to degrade the mRNA targets or restrain their
translation [48]. There are multiple mechanisms of
miRNAs regulation on PD pathogenesis. For example,
miR-7 and miR-153 modulate the mRNA level of α-
synuclein [49], LRRK2 contributes to the regulation of
E2F1/DP expression which is affected by miR-7 and
miR-184 [50]. Recent studies mainly focused on the
microglia activation and macrophage infiltration in
brain. It becomes a hot spot about the mechanism of
miRNAs modulating the related inflammatory disorders
in CNS. Based on function classification, some micro-
RNAs are classified as pro-inflammatory molecules, such
as miR-155, miR-125 and miR-101, and some are anti--
inflammatory molecules, such as miR-146, miR-21 and
miR-124 [51]. It was reported that miR-146 modulates
the microglia activation in CNS regulated by NF-KB and
JNK-STAT (Janus kinase/signal transducers and
activators of transcription) pathways, miR-124 retrains
macrophage and microglia activation conducted by
CCAAT-enhancer-binding proteins-α–PU.1 complex
[52, 53]. All the miRNAs are involved in the inflamma-
tion/immunity system on PD pathogenesis [54].
Furthermore, the decreased level of miR-141, miR-
214、miR-146b-5p and miR-193a-3p was found closely
associated with the early stage of PD [55]. In our study,
there were 644 abnormal miRNAs detected in A53T-PD
transgenic mice using high-throughput screening.
Among them, 72 miRNAs were confirmed to involve in
the immune response in SN. The level of 42 miRNAs
has changed significantly in midbrain, such as
miR-146b-5 decreases to 0.45 fold, whereas miR-124-
5p up to 0.44 fold. Several miRNAs were confirmed
to be stable in blood, urine and CSF, so called circu-
lating miRNAs [56]. We also screened out 10
circulating miRNAs in CSF samples from 40 Chinese
PD patients for disease’s inflammatory evaluation [57].
Among them, miR-200a-3p and miR-542-5p were
supposed to be closely related to α-synuclein aggrega-
tion, whereas miR-342-5p was proved to participate
in modulating inflammatory reaction [57]. These cir-
culating miRNAs are ideal biomarkers for the evalu-
ation of CNS diseases.
Conclusions
In summary, the interaction of aging, environment risk
and genetic factors results in the accumulation of α-sy-
nuclein in midbrain which ignites the special inflamma-
tory /immune response medicated by i-proteasome. In
the inflammatory/immune procession, MHC signal path-
way accompanied with microglia activation is vital to
DA neurons apoptosis. Taking together, α-synuclein ac-
cumulation and abnormal MHC antigenic presentation
cause inflammation/immune response in CNS and pro-
vide specific biomarkers for the prediction of DA neu-
rons degeneration and assessment of PD risk as well as
PD development (Table 1).
Table 1 The biomarkers of immune dysregulation and
inflammation response in PD
Immunological
genes
PSMB9-rs17587, HLA-DRA, HLA-DRB1*0404,
HLA-DRB1*0301, HLA-C*0304, HLA-DQB1, etc.
PD related genes PARK1, PARK2, PINK1, DJ-1, ATP13a2, GBA,
RAB7L1-NUCKS1, STK39, BST1, FAM47E-SCARB2,
SNCA, HLA, GPNMB, FGF20, LRRK2, GCH1,
MAPT, SREBF1, DDRGK1, NURR1, etc.
Proteins in CSF a-synuclein, Aβ42, Tau, Nurr1, etc.
Inflammation factors TNF-α, IL-2, IL-6, IL-10, IL-1β, IFN-γ, etc.
Antibodies ICAM4, PTCD2, FRMD8, CTLA-4/Fc, MYOT, HSH2D,
FN1, TRIM21, Elongation factor 1-alpha 1,
PABPC3, etc.
Blood lymphocytes CD3+, CD4+, CD8+, CD31+ α4β7+ CD4+, CD95/CD3,
NK cells, etc.
PD related miRNAs miR-7, miR-153, miR-155, miR-125, miR-101,
miR-146, miR-21, miR-124, miR-141, miR-214,
miR-146b-5p, miR-193a-3p, miR-200a-3p,
miR-542-5p, miR-342-5p, etc.
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